Jenburkt Pharmaceuticals logo

Jenburkt Pharmaceuticals

JENBURPH NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹452 Cr
Volatility
High Risk
P/E Ratio
13.5
EBITDA
₹54.00 Cr
Return on Equity
17.63%
Debt to Equity
0.01
Book Value
₹446.47
52W High
₹1,073.9
52W Low
₹1,000

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 25.7%

Weaknesses

1
  • The company has delivered a poor sales growth of 9.08% over past five years.

Growth Rate

Revenue Growth
13.01% higher than 3Y
Net Income Growth
8.1% lower than 3Y
Cash Flow Change
-4.98% lower than 3Y
ROE
-5.52% lower than 3Y
ROCE
-7.43% lower than 3Y
EBITDA Margin (Avg.)
1.48% lower than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
29.18
38.29
35.66
38.84
32.54
41.22
36.89
41.05
35.53
45.56
43.02
44.63
35.51
Expenses
22.22
29.19
28.47
28.99
23.26
29.79
28.07
30.19
26.58
32.45
35.59
30.38
29.48
Operating Profit
6.96
9.1
7.19
9.85
9.28
11.43
8.82
10.86
8.95
13.11
7.43
14.25
6.03
OPM %
23.85%
23.77%
20.16%
25.36%
28.52%
27.73%
23.91%
26.46%
25.19%
28.78%
17.27%
31.93%
16.98%
Other Income
1.04
1.1
1.35
1.19
1.41
1.85
1.58
1.88
2.06
2.08
1.82
0.4
1.51
Interest
0.07
0.07
0.07
0.06
0.11
0.12
0.11
0.11
0.11
0.11
0.12
0.13
0.13
Depreciation
0.5
0.59
0.63
0.62
0.52
0.64
0.78
0.79
0.72
0.74
0.83
0.81
0.64
PBT
7.43
9.54
7.84
10.36
10.06
12.52
9.51
11.84
10.18
14.34
8.3
13.71
6.77
Tax %
27.73%
23.27%
31.12%
23.94%
26.34%
23.32%
31.65%
27.87%
23.48%
29.08%
28.55%
20.86%
13%
Net Profit
5.37
7.32
5.4
7.88
7.42
9.6
6.51
8.54
7.79
10.16
5.93
10.85
5.89
EPS in Rs
12.17
16.59
12.24
17.86
16.81
21.75
14.75
19.35
17.65
23.02
13.44
24.58
13.35
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
85
94
103
115
123
119
109
124
137
142
152
169
169
Expenses
70
77
84
91
98
99
89
97
106
109
111
125
128
Operating Profit
15
16
20
24
25
20
20
27
30
33
40
44
41
OPM %
18%
18%
19%
21%
20%
17%
18%
22%
22%
23%
27%
26%
24%
Other Income
2
3
3
3
3
4
4
5
5
5
7
6
6
Interest
0
0
0
0
0
1
0
0
0
0
0
0
0
Depreciation
3
2
2
2
1
2
2
2
2
2
3
3
3
PBT
14
17
20
25
27
21
22
30
33
35
44
47
43
Tax %
33%
36%
34%
32%
26%
30%
24%
25%
25%
26%
27%
25%
—
Net Profit
10
11
14
17
20
15
16
22
25
26
32
35
33
EPS in Rs
20.76
23.19
29.06
37.5
43.14
32.4
35.95
48.59
55.76
58.87
72.64
78.72
74.39
Div. Payout %
30%
31%
28%
24%
24%
25%
28%
25%
26%
26%
25%
26%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5
5
5
5
5
5
5
5
4
4
4
4
Reserves
29
36
50
57
73
75
94
113
118
141
167
193
Borrowings
7
5
6
0
7
3
5
7
3
0
4
2
Other Liabilities
21
12
16
16
18
21
17
18
16
19
19
26
Total Liabilities
61
58
76
77
103
104
120
143
141
164
195
225
Fixed Assets
12
12
11
10
10
12
11
11
10
10
15
19
CWIP
0
0
0
0
1
0
0
0
1
1
40
46
Investments
0
1
2
5
5
4
7
8
11
17
21
27
Other Assets
49
45
64
62
87
88
103
123
119
136
120
132
Total Assets
61
58
76
77
103
104
120
143
141
164
195
225
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
9
8
10
16
13
15
19
9
17
8
28
27
Investing
1
0
-10
1
-11
-3
-19
-1
3
-1
-17
-19
Financing
1
-5
1
-18
-2
-11
-1
-6
-21
-7
-8
-9
Net Cash Flow
11
2
1
-1
0
1
0
3
-1
0
3
-2
Free Cash Flow
8
5
10
16
11
11
18
7
15
6
8
13
CFO/OP
88
82
85
103
80
104
127
62
83
49
102
88
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
32
23
32
40
68
55
47
45
45
50
50
53
Inventory Days
107
109
128
73
99
120
92
115
92
103
109
154
Days Payable
54
44
72
44
66
58
56
83
67
75
100
91
Cash Conversion Cycle
85
88
89
69
101
117
83
77
70
78
59
115
Working Capital Days
-11
6
10
25
35
32
17
16
31
36
31
41
ROCE %
42%
40%
39%
42%
37%
26%
24%
26%
27%
26%
27%
27%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Jenburkt Pharmaceuticals insights

62 extracted metrics + investor summaries across FY10–FY26.

Log in — free

Shareholding Pattern

DIIs0.12%Promot.46.62%Others12.21%Public41.05%As ofJun 2026

Documents

Frequently Asked Questions about Jenburkt Pharmaceuticals

What does Jenburkt Pharmaceuticals Ltd do?
Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]
Where is Jenburkt Pharmaceuticals Ltd (524731) listed?
Jenburkt Pharmaceuticals Ltd trades as JENBURPH on the NSE and under code 524731 on the BSE.
Which sector does Jenburkt Pharmaceuticals Ltd belong to?
Jenburkt Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd has a market capitalisation of ₹452.36 Cr, which places it in the Small Cap band.
What is the PE ratio of Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd trades at a PE ratio of 13.50, against a book value of ₹446.47 per share.
What is the 52-week high and low of Jenburkt Pharmaceuticals Ltd?
Over the last 52 weeks Jenburkt Pharmaceuticals Ltd has traded between ₹1,000 and ₹1,073.9.
Does Jenburkt Pharmaceuticals Ltd pay dividends?
Jenburkt Pharmaceuticals Ltd has a dividend yield of 2.02%.
What is the Return on Equity (ROE) of Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd reported a return on equity of 17.63%. Its debt-to-equity ratio is 0.01.

Company Information

Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]

Website jenburkt.com
Listed 2026-08-17
Face Value ₹ 10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524731.md for Jenburkt Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List